Jan-Willem Alffenaar at The University of Sydney - Research Interests, Publications & Academic Profile

Jan-Willem Alffenaar

University of Sydney

Australia

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do Korean students reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacotherapy

70%

Pharmacology

70%

Tuberculosis Research

40%

Drug Repurposing

30%

Antibiotic Therapy

30%

Pharmacoepidemiology

30%

Antifungal Therapy

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles11

Population Pharmacokinetics and Dose Evaluation of Cycloserine among Patients with Multidrug-Resistant Tuberculosis under Standardized Treatment Regimens

Article Link

Year:

2023

Meropenem-vaborbactam restoration of first-line drugs’ efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen

Article Link

Year:

2023

Medicinal cannabis for Australian patients with chronic refractory pain including arthritis

Article Link

Year:

2023

Medicinal cannabis for patients with chronic non-cancer pain: analysis of safety and concomitant medications

Article Link

Year:

2023

Implementing Innovative Approaches to Improve Health Care Delivery Systems for Integrating Communicable and Non-Communicable Diseases Using Tuberculosis and Diabetes as a Model in Tanzania

Article Link

Year:

2023

Impact of COVID-19 on diagnosis of tuberculosis, multidrug-resistant tuberculosis, and on mortality in 11 countries in Europe, Northern America, and Australia. A Global Tuberculosis Network study

Article Link

Year:

2023

Is there a need to optimise pyrazinamide doses in patients with tuberculosis? A systematic review

Article Link

Year:

2023

Exploring synergy between azole antifungal drugs and statins for <i>Candida auris</i>

Article Link

Year:

2023

Dried Blood Spot Sampling to Assess Rifampicin Exposure and Treatment Outcomes among Native and Non-Native Tuberculosis Patients in Paraguay: An Exploratory Study

Article Link

Year:

2023

Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practice

Article Link

Year:

2023

Alternative Methods for Therapeutic Drug Monitoring and Dose Adjustment of Tuberculosis Treatment in Clinical Settings: A Systematic Review

Article Link

Year:

2023

Collaborators11

Shashikant Srivastava

Associate Professor of Pulmonary Immunology

The University of Texas Health Science Center at Tyler

UNITED STATES

Lina Davies Forsman

Karolinska Institutet

SWEDEN

Troels Lillebaek

Københavns Universitet

DENMARK

Marieke G. G. Sturkenboom

University Medical Center Groningen

NETHERLANDS

Dirk Lund Christensen

Københavns Universitet

DENMARK

Nial Wheate

Associate Professor

University of Sydney

AUSTRALIA

Sophie Stocker

Senior Lecturer

University of Sydney

AUSTRALIA

Tania Thomas

Associate Professor

Virginia Commonwealth University Medical Center

UNITED STATES

Ib Bygbjerg

Københavns Universitet

DENMARK

FX Blanc

Professor of Respiratory Medicine

Université de Nantes

FRANCE

Cecile Magis-Escurra

NETHERLANDS

How do Korean students reach out?

Meet Kite AI